ANTI INTERLEUKIN-1 PADA COVID-19

Fariz Nurwidya, Itsna Arifatuz Zulfiyah

Abstract


Pada coronavirus infectious disease (COVID-19) terjadi invasi virus SARS-COV2 pada epitel alveolar. Sel epitel alveolar yang terinfeksi akan mengekpresikan antigen virus pada permukaan sel yang kemudian memicu respon rekognisi oleh makrofag. Sel makrofag ini kemudian mensekresikan interleukin-1 (IL-1) untuk aktivasi respon seluler. Metode, dilakukan penelusuran bukti ilmiah menggunakan kata kunci IL-1, Covid-1 dan inhibitor IL-1 pada database ilmiah PubMed dan Google Scholar. Hasil, pasien COVID-19 memiliki peningkatan kadar IL-1 pada darah dan berhubungan dengan severitas penyakit. Penggunaan zat biologik yang mentarget secara spesifik jalur yang mengalami hiperaktivasi pada pasien COVID-19 adalah salah satu strategi untuk mengatasi hiperinflamasi. Beberapa penelitian uji klinis telah dilakukan menggunakan IL-1 inhibitor pada pasien COVID-19 derajat berat dan mengancam jiwa. Kesimpulan, tinjauan pustaka ini menemukan bahwa IL-1 berperan pada kaskade inflamasi pasien COVID-19 dan inhibisi IL-1 sebagai salah satu cara untuk mengatasi proses inflamasi pada pasien COVID-19 derajat berat.

Keywords


interleukin-1; COVID-19; IL-1 inhibitor

Full Text:

PDF

References


Kim JS, Lee JY, Yang JW, Lee KH, Effenberger M, Szpirt W, et al. Immunopathogenesis and treatment of cytokine storm in COVID-19. Theranostics. 2021;11(1):316–29.

Ucciferri C, Vecchiet J, Falasca K. Role of monoclonal antibody drugs in the treatment of COVID-19. World J Clin Cases. 2020;8(19):4280–5.

Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363–74.

Quirch M, Lee J, Rehman S. Hazards of the Cytokine Storm and Cytokine-Targeted Therapy in Patients With COVID-19: Review. J Med Internet Res. 2020;22(8):e20193.

Schulert GS, Grom AA. Macrophage activation syndrome and cytokine-directed therapies. Best Pract Res Clin Rheumatol. 2014;28(2):277–92.

Grom AA, Horne A, De Benedetti F. Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol. 2016;12(5):259–68.

The RCI-COVID-19 Study Group, Kooistra EJ, Waalders NJB, Grondman I, Janssen NAF, de Nooijer AH, et al. Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study. Crit Care. 2020;24(1):688.

King A, Vail A, O’Leary C, Hannan C, Brough D, Patel H, et al. Anakinra in COVID-19: important considerations for clinical trials. Lancet Rheumatol. 2020;2(7):e379–81.

Cauchois R, Koubi M, Delarbre D, Manet C, Carvelli J, Blasco VB, et al. Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19. Proc Natl Acad Sci. 2020;117(32):18951–3.

Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020;2(6):e325–31.

Huet T, Beaussier H, Voisin O, Jouveshomme S, Dauriat G, Lazareth I, et al. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol. 2020;2(7):e393–400.

Cavalli G, Larcher A, Tomelleri A, Campochiaro C, Della-Torre E, De Luca G, et al. Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study. Lancet Rheumatol. 2021;S2665991321000126.

Cavalli G, Dagna L. The right place for IL-1 inhibition in COVID-19. Lancet Respir Med. 2021;9(3):223–4.

Hossen MdS, Barek MA, Jahan N, Safiqul Islam M. A Review on Current Repurposing Drugs for the Treatment of COVID-19: Reality and Challenges. SN Compr Clin Med. 2020;2(10):1777–89.

Katia F, Myriam DP, Ucciferri C, Auricchio A, Di Nicola M, Marchioni M, et al. Efficacy of canakinumab in mild or severe COVID‐19 pneumonia. Immun Inflamm Dis. 2021;iid3.400.

Generali D, Bosio G, Malberti F, Cuzzoli A, Testa S, Romanini L, et al. Canakinumab as treatment for COVID-19-related pneumonia: A prospective case-control study. Int J Infect Dis. 2021;104:433–40.

Ucciferri C, Auricchio A, Di Nicola M, Potere N, Abbate A, Cipollone F, et al. Canakinumab in a subgroup of patients with COVID-19. Lancet Rheumatol. 2020;2(8):e457-ee458.

Landi L, Ravaglia C, Russo E, Cataleta P, Fusari M, Boschi A, et al. Blockage of interleukin-1β with canakinumab in patients with Covid-19. Sci Rep. 2020;10(1):21775.




DOI: https://doi.org/10.36409/jika.v9i1.242

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.